Basel Medical Group has approved a 1-for-12 reverse stock split designed to support compliance with Nasdaq listing requirements.

Basel Medical Group (NASDAQ: BMGL) announced that it will implement a 1-for-12 reverse stock split effective June 22, 2026.

The action is intended to help the company satisfy Nasdaq's minimum bid price requirement. Following the reverse split, the company's outstanding share count is expected to decline from approximately 18.8 million shares to about 1.57 million shares.

Reverse stock splits are commonly used by companies seeking to maintain exchange listing compliance while potentially improving institutional investor perception. The transaction changes the number of shares outstanding but does not directly alter the company's overall market capitalization.

Investors will be monitoring trading activity after the split takes effect and assessing whether the move successfully supports Nasdaq compliance efforts.